Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Transl Gastroenterol ; 15(3): e00679, 2024 03 01.
Article in English | MEDLINE | ID: mdl-38251689

ABSTRACT

INTRODUCTION: Isolated case reports and case series have linked the use of sevelamer to severe gastrointestinal (GI) inflammation and perforation among patients with end-stage renal disease. METHODS: In this study, we identified 12 cases of biopsy-proven sevelamer-induced gastrointestinal disease from a large urban community hospital over the course of 5 years. We described baseline characteristics, sites and types of injury, histological findings, timing and dosing of sevelamer initiation compared with symptom onset, and in a smaller subset, endoscopic resolution post drug cessation. We also reviewed preexisting conditions to identify trends in populations at risk. RESULTS: Several of the patients reviewed had preexisting conditions of decreased motility and/or impaired mucosal integrity. The presentation of disease was broad and included both upper-GI and lower-GI pathologies and in varying severity. DISCUSSION: There is a broad phenotypic range of sevelamer-induced gastrointestinal disease. As this becomes a more frequently recognized pathology, clinicians should be aware of how it may present and which populations may be more susceptible.


Subject(s)
Gastrointestinal Diseases , Kidney Failure, Chronic , Humans , Sevelamer/adverse effects , Chelating Agents/adverse effects , Renal Dialysis/adverse effects , Gastrointestinal Diseases/chemically induced , Gastrointestinal Diseases/diagnosis
2.
Transpl Infect Dis ; 23(3): e13562, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33432726

ABSTRACT

Donor-derived (DD) herpes simplex virus (HSV) hepatitis in solid organ transplant (SOT) recipients is extremely uncommon but carries a high mortality rate. The diagnosis is challenging due to the non-specific presentation and lack of clinical suspicion. We report a case of DDHSV hepatitis in a HSV2 pre-transplant seronegative kidney recipient who received the organ from a HSV2 seropositive donor. The case is highlighted by a few unusual features, namely severe thrombocytopenia and the development of cutaneous, oral and esophageal HSV lesions several weeks after symptom onset while recovering on appropriate treatment. A review of nine proven and probable DDHSV hepatitis cases (including eight previously published ones) showed that fever is a common presenting feature while gastrointestinal symptoms and cutaneous manifestations are uncommon. The symptoms almost always occurred within 2 weeks of transplant. Six out of the nine DDHSV hepatitis patients, including five patients who were on appropriate treatment, died within a month after transplant.


Subject(s)
Hepatitis, Viral, Human , Herpes Simplex , Kidney Transplantation , Humans , Simplexvirus , Tissue Donors
3.
Transpl Infect Dis ; 22(2): e13259, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32034980

ABSTRACT

Cytomegalovirus (CMV) is a common opportunistic infection in solid organ transplant (SOT) recipients in the first 6 months after transplant. Late onset CMV infection or disease outside the classical risk period is uncommon and can present with atypical signs and symptoms. Here, we report a case of late onset CMV presenting as a colonic stricture more than 10 years after liver transplantation in the absence of traditional CMV risk factors. We also briefly review CMV colitis presenting as a mass or stricture in SOT recipients.


Subject(s)
Colitis/virology , Colon/pathology , Cytomegalovirus Infections/diagnosis , Liver Transplantation/adverse effects , Aged , Antiviral Agents/therapeutic use , Colitis/diagnosis , Constriction, Pathologic , Cytomegalovirus , Cytomegalovirus Infections/drug therapy , Female , Humans , Male , Risk Factors , Sigmoidoscopy
4.
Liver Transpl ; 24(11): 1561-1569, 2018 11.
Article in English | MEDLINE | ID: mdl-29694710

ABSTRACT

Liver transplantation (LT) is hospital-resource intensive and associated with high rates of readmission. We have previously shown a reduction in 30-day readmission rates by implementing a specifically designed protocol to increase access to outpatient care. The aim of this work is to determine if the strategies that reduce 30-day readmission after LT were effective in also reducing 90-day readmission rates and costs. A protocol was developed to reduce inpatient readmissions after LT that expanded outpatient services and provided alternatives to readmission. The 90-day readmission rates and costs were compared before and after implementing strategies outlined in the protocol. Multivariable analysis was used to control for potential confounding factors. Over the study period, 304 adult primary LTs were performed on patients with a median biological Model for End-Stage Liver Disease of 22. There were 112 (37%) patients who were readmitted within 90 days of transplant. The readmission rates before and after implementation of the protocol were 53% and 26%, respectively (P < 0.001). The most common reason for readmission was elevated liver tests/rejection (24%). In multivariable analysis, the protocol remained associated with avoiding readmission (odds ratio, 0.33; 95% confidence interval, 0.20-0.55; P < 0.001). The median length of stay after transplant before and after protocol implementation was 8 days and 7 days, respectively. A greater proportion of patients were discharged to hospital lodging after protocol implementation (10% versus 19%; P = 0.03). The 90-day readmission costs were reduced by 55%, but the total 90-day costs were reduced by only 2.7% because of higher outpatient costs and index admission costs. In conclusion, 90-day readmission rates and readmission costs can be reduced by improving access to outpatient services and hospital-local lodging. Total 90-day costs were similar between the 2 groups because of higher outpatient costs after the protocol was introduced.


Subject(s)
Cost Savings/methods , End Stage Liver Disease/surgery , Liver Transplantation/adverse effects , Patient Readmission/statistics & numerical data , Postoperative Complications/prevention & control , Adult , Aged , Ambulatory Care/economics , Ambulatory Care/statistics & numerical data , Cost Savings/economics , Cost Savings/statistics & numerical data , Critical Pathways/economics , End Stage Liver Disease/economics , Female , Health Services Accessibility/economics , Health Services Accessibility/statistics & numerical data , Hospital Costs/statistics & numerical data , Humans , Length of Stay/economics , Length of Stay/statistics & numerical data , Liver Transplantation/economics , Liver Transplantation/methods , Male , Middle Aged , Patient Readmission/economics , Postoperative Complications/economics , Postoperative Complications/etiology , Prospective Studies , Retrospective Studies , Risk Factors , Time Factors
5.
Clin Transl Gastroenterol ; 8(10): e124, 2017 Oct 19.
Article in English | MEDLINE | ID: mdl-29048416

ABSTRACT

OBJECTIVES: The basis for over-representation of colorectal cancer (CRC) in African-American (AA) populations compared with Caucasians are multifactorial and complex. Understanding the mechanisms for this racial disparity is critical for delivery of better care. Several studies have investigated sporadic CRC for differences in somatic mutations between AAs and Caucasians, but owing to small study sizes and conflicting results to date, no definitive conclusions have been reached. METHODS: Here, we present the first systematic literature review and meta-analysis investigating the mutational differences in sporadic CRC between AAs and Caucasians focused on frequent driver mutations (APC,TP53, KRAS,PI3CA, FBXW7,SMAD4, and BRAF). Publication inclusion criteria comprised sporadic CRC, human subjects, English language, information on ethnicity (AA, Caucasian, or both), total subject number >20, and information on mutation frequencies. RESULTS: We identified 6,234 publications. Meta-analysis for APC, TP54, FBXW7, or SMAD4 was not possible owing to paucity of data. KRAS mutations were statistically less frequent in non-Hispanic Whites when compared with AAs (odds ratio, 0.640; 95% confidence interval (CI): 0.5342-0.7666; P=0.0001), while the mutational differences observed in BRAF and PI3CA did not reach statistical significance. CONCLUSIONS: Here, we report the mutational patterns for KRAS, BRAF, and PI3CA in sporadic CRC of AAs and Caucasians in a systematic meta-analysis of previously published data. We identified an increase in KRAS mutations in sporadic CRC in AAs, which may contribute to worse prognosis and increased mortality of CRC in AAs. Future studies investigating health-care disparities in CRC in AAs should control for KRAS mutational frequency.

6.
Dent Clin North Am ; 61(2): 271-282, 2017 04.
Article in English | MEDLINE | ID: mdl-28317566

ABSTRACT

Osteomyelitis is an inflammation of bone marrow with a tendency for progression, involving the cortical plates and often periosteal tissues, with most cases occurring after trauma to bone or bone surgery or secondary to vascular insufficiency. Antimicrobial therapy and surgical débridement are the primary modalities of osteomyelitis treatment, although often it is associated with a prolonged course, requiring a large commitment between patient and clinician as well as sizable health care costs. Despite surgical and chemotherapeutic advancements, osteomyelitis remains difficult to treat, and no universally accepted protocol for treatment exists.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Osteomyelitis/drug therapy , Osteomyelitis/microbiology , Acute Disease , Chronic Disease , Humans , Osteomyelitis/classification
7.
Dent Clin North Am ; 60(2): 367-79, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27040290

ABSTRACT

Pharmacologic agents play an integral role in the overall management of temporomandibular joint disorder. The general dentist should be familiar with the different classes of drugs currently in use for dealing with this often complex medical/dental problem.


Subject(s)
Pharmaceutical Preparations, Dental/therapeutic use , Temporomandibular Joint Disorders/drug therapy , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...